Evidence map›Paper›PMID 12041913›Full record

ArticleEndocrine2002

Glucocorticoid inhibition of 235-1 rat pituitary tumor cell cycle progression.

Beverly C Delidow, Miranda Wang, Sonita V Bhamidipaty, Lynn D Black

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Beverly C DelidowDepartment of Biochemistry and Molecular Biology, Marshall University School of Medicine, Huntington, WV 25704, USA. delidow@marshall.edu
Miranda Wang
Sonita V Bhamidipaty
Lynn D Black
Marshall University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Control of the cell cycle is accomplished by sequentially activated cyclin-dependent kinases and the action of inhibitory proteins. We have shown that exposure of 235-1 rat pituitary tumor cells to dexamethasone (DEX) leads to a 50% reduction in growth rate. We examined the mechanism by which DEX affects 235-1 cell proliferation by determining the expression levels of proteins involved in cell-cycle progression. The expression of the G1 markers c-Myc and cyclin D3 were unaffected by DEX treatment. Levels of retinoblastoma family proteins p107 and p116 Rb were not altered. The levels of p1 30/Rb2 were increased by DEX within 36 h of initiating treatment. Additionally, a higher-mobility Rb2-related protein appeared within 24 h and was further increased in DEX-treated cells by 36 h. We also observed reduced levels of M-phase proteins, Cdc2 kinase, and cyclin B in DEX-treated cells. These changes occurred prior to the reduction in cell numbers and thus may represent causative factors. Our data suggest that DEX induces a late G1 block in 235-1 cell-cycle passage, accompanied by a reduction in the levels of the regulatory proteins required for passage through subsequent phases of the cell cycle.

Indexed as

AnimalsBlotting, NorthernBlotting, WesternCDC2 Protein KinaseCell CycleCell Cycle ProteinsCell DivisionCyclin BCyclin B1Cyclin D3Cyclin-Dependent Kinase Inhibitor p27CyclinsDexamethasoneGlucocorticoidsPituitary NeoplasmsProlactinomaCcnb1 protein, ratCcnd3 protein, ratCDC2 Protein KinaseCdkn1b protein, ratCell Cycle ProteinsCyclin BCyclin B1Cyclin D3Cyclin-Dependent Kinase Inhibitor p27CyclinsDexamethasoneGlucocorticoidsProto-Oncogene Proteins c-mycRetinoblastoma ProteinRNA, NeoplasmTumor Suppressor Proteins

Identifiers

PMID12041913
OpenAlexW2083013219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.